IMCR vs RARE · rev $222.6M vs rev $350.0M
Immunocore Holdings Ltd (IMCR) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Immunocore Holdings Ltd (IMCR) is a biotechnology company listed on NASDAQ.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported IMCR revenue for 2026-06-30 was $222.6M. Net income was $12.2M. IMCR currently screens at market cap $1.45B.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
IMCR currently screens at market cap $1.45B. RARE currently screens at market cap $2.79B.
Not investment advice. Open the IMCR and RARE stock pages for the full models.
Not investment advice.